Rituximab Biosimilars Produce Comparable Outcomes in Diffuse Large B-Cell Lymphoma
Response and survival outcomes were similar with rituximab biosimilars and the originator.
Response and survival outcomes were similar with rituximab biosimilars and the originator.
Researchers sought to determine the fertility-related issues and approaches for survivors of Hodgkin lymphoma and diffuse large B-cell lymphoma.
This case study showed that B-cell type primary central nervous system lymphoma may rapidly progress following dimethyl fumarate treatment in patients with relapsing remitting MS.
Circulating tumor DNA may identify patients at risk of relapse after axicabtagene ciloleucel.
Researchers sought to develop a low-cost, machine learning-based approach to diagnosing paraffin-embedded lymphoma biopsy specimens.
Researchers sought to determine whether a novel model that combines signatures of metabolic dysregulation with clinical features may aid in clinical decision-making among patients with DLBCL.
Researchers sought to determine the maximum and recommended phase 2 dose for loncastuximab tesirine in patients with B-cell NHL.
Researchers sought to identify factors that may contribute to failure with CAR T cell therapy in patients with LBCL.
This analysis compared infection-related hospitalization and death among patients 70 years of age and older with DLBCL treated with full-dose vs attenuated-dose R-CHOP.
Researchers sought to determine whether C-CAR039 would be safe and effective in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.